VYGR Share Price Performance
US$3.85
-0.03 (-0.90%)
84.6% undervalued intrinsic discount
US$25.00
Fair Value
Price US$3.85
AnalystHighTarget US$25.00
AnalystConsensusTarget US$15.74
AnalystLowTarget US$8.00
Fair ValueUS$25.00
Share Pricen/a
Voyager Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
VYGR Community Narratives
AN
Fair Value US$25 84.6% undervalued intrinsic discount
Gene Therapy Advances Will Unlock Neurodegenerative Markets
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$15.67 75.5% undervalued intrinsic discount
Tau-Targeting Therapies May Transform Alzheimer's Treatment Despite Clinical Uncertainties
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value US$8 51.9% undervalued intrinsic discount
Gene Therapy Competition Will Curb Progress Yet Allow Modest Breakthroughs
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Gene Therapy Advances Will Unlock Neurodegenerative Markets
Key Takeaways Innovative gene therapy platforms and a growing pipeline position Voyager for long-term growth and expanded partnership opportunities in neurodegenerative disease treatment. Advancing clinical programs and industry partnerships enhance de-risking, commercial prospects, and recurring revenue streams as regulatory and market acceptance rises.Read more
44
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$25
84.6% undervalued intrinsic discount
Fair Value
Profit Margin
1.83%
Future PE
545.9x
Price in 2029
US$30.91
Gene Therapy Competition Will Curb Progress Yet Allow Modest Breakthroughs
Key Takeaways Heavy reliance on a small set of programs and selective partnerships increases risk, as setbacks or partner changes could sharply reduce revenue growth and licensing income. Delays from regulatory scrutiny and emerging competition in gene therapies threaten timely growth, while persistent expenses and pricing pressures could weaken profit margins.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$8
51.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
177.94x
Price in 2028
US$9.78
Tau-Targeting Therapies May Transform Alzheimer's Treatment Despite Clinical Uncertainties
Key Takeaways Voyager Therapeutics' innovative focus on tau-targeting programs in Alzheimer's could capture significant market demand, boosting future earnings and revenue. Strategic partnerships and promising technological advancements ensure non-dilutive revenue growth and potential stock revaluation, enhancing long-term net margins and earnings per share.Read more
87
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
US$15.67
75.5% undervalued intrinsic discount
Fair Value
Profit Margin
14.17%
Future PE
85.3x
Price in 2028
US$19.15
Trending Discussion
Recently Updated Narratives
AN
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Fair Value: US$25 84.6% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Gene Therapy Competition Will Curb Progress Yet Allow Modest Breakthroughs
Fair Value: US$8 51.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Tau-Targeting Therapies May Transform Alzheimer's Treatment Despite Clinical Uncertainties
Fair Value: US$15.67 75.5% undervalued intrinsic discount
9 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Voyager Therapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -2.01
- -227.62%
- -296.53%
- 0%
About VYGR
- Founded
- 2013
- Employees
- 141
- CEO
- WebsiteView website
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
